Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksABC.L Regulatory News (ABC)

  • There is currently no data for ABC

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Total Voting Rights

2 Jun 2014 08:30

RNS Number : 5619I
ABCAM Plc
02 June 2014
 



For immediate release

2 June 2014

ABCAM PLC

("Abcam" or "the Company")

Total Voting Rights - Voting Rights and Capital

In conformity with 5.6.1 of the Disclosure and Transparency Rules, the Company notifies the market of the following: The Company's issued share capital consists of 200,446,300 Ordinary Shares of 0.2p each with voting rights. The Company does not hold any shares in Treasury.The above figure of 200,446,300 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FSA's Disclosure and Transparency Rules.

Date of Notification: 2 June 2014

For further information please contact:

Abcam

+ 44 (0) 1223 696 000

Jeff Iliffe, Chief Financial Officer

 

Numis Securities - Nominated Adviser & Joint Broker

+ 44 (0) 20 7260 1000

Michael Meade - Nominated Adviser

James Black - Corporate Broking

 

Peel Hunt LLP - Joint Broker

+ 44 (0) 20 7418 8900

Clare Terlouw / Jock Maxwell MacDonald

 

Buchanan

+ 44 (0) 20 7466 5000

Mark Court / Fiona Henson / Sophie Cowles

 

Notes for editors:

About Abcam plc

Abcam plc is a leading provider of protein research tools and services, with a wide range of products and expert technical support, enabling scientists to analyse living cells at the molecular level to improve the understanding of health and disease.

 

Abcam is committed to providing scientists with access to the correct reagents and tools for their research. The Company's catalogue currently comprises more than 132,000 products and is continually evolving to meet customer needs. The range offered includes primary and secondary antibodies, proteins, peptides, lysates, biochemicals, immunoassays and other kits. Abcam products are supported with detailed, up-to-date and unbiased data on our website.

 

Headquartered in Cambridge, UK, Abcam has eight global subsidiary offices and ships to over 100 countries. The Company was founded in 1998, and now employs over 700 people. Abcam is quoted on the AIM market of the London Stock Exchange (AIM: ABC).

 

To find out more, please visit www.abcam.com 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TVRUGUMPQUPCUMP
Date   Source Headline
7th Jun 20067:00 amRNSTrading Update
9th May 20067:02 amRNSCommercial Development Appt.
27th Mar 200612:06 pmRNSDirector/PDMR Shareholding
14th Feb 20067:01 amRNSInterim Results
31st Jan 20067:01 amRNSNotification of Results
22nd Dec 20054:08 pmRNSDirectors Shareholding
3rd Nov 20057:00 amRNSFirst Day of Dealings

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.